News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

  • KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results

  • Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement

  • KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital

  • KemPharm Reports Third Quarter 2019 Results

  • KemPharm to Report Third Quarter 2019 Results

  • KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019

  • KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting

  • KemPharm Provides Updates Regarding its Board of Directors

  • KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases

  • KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.

  • KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital